Evaxion A/S (EVAX)
NASDAQ: EVAX · Real-Time Price · USD
3.270
+0.050 (1.55%)
At close: Sep 18, 2026, 4:00 PM EDT
3.320
+0.050 (1.53%)
After-hours: Sep 18, 2026, 7:57 PM EDT
Evaxion Employees
Evaxion had 46 employees as of December 31, 2025. The number of employees did not change compared to the previous year.
Employees
46
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$162,848
Profits / Employee
-$188,152
Market Cap
27.27M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 46 | 0 | - |
| Dec 31, 2024 | 46 | -3 | -6.12% |
| Dec 31, 2023 | 49 | -14 | -22.22% |
| Dec 31, 2022 | 63 | 2 | 3.28% |
| Dec 31, 2021 | 61 | 26 | 74.29% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| IGC Pharma | 70 |
| BeyondSpring | 44 |
| NextCure | 40 |
| Quince Therapeutics | 38 |
| Kyntra Bio | 34 |
| ABVC BioPharma | 19 |
| Quantum BioPharma | 17 |
| Atossa Therapeutics | 16 |
EVAX News
- 5 days ago - Evaxion applies its AI-Immunology™ platform in autoimmune diseases - GlobeNewsWire
- 4 weeks ago - Evaxion Earnings Call Transcript: Q2 2026 - Transcripts
- 4 weeks ago - Evaxion Earnings release: Q2 2026 - Filings
- 4 weeks ago - Evaxion Slides: Q2 2026 - Filings
- 4 weeks ago - Evaxion announces business update and second quarter 2026 financial results - GlobeNewsWire
- 4 weeks ago - Evaxion expands and refocuses R&D pipeline with EVX-05, an AI-designed off-the-shelf brain cancer vaccine program - GlobeNewsWire
- 5 weeks ago - Evaxion to announce business update and second quarter 2026 financial results on August 20, 2026 - GlobeNewsWire
- 5 weeks ago - Merck discloses 1.21M share holding in Evaxion Biotech - TheFly